An internationally-recognized leader in the field of hepatitis C, Dr. Ira M. Jacobson (Chief, Division of Gastroenterology and Hepatology) has been at the forefront of hepatitis C for more than 20 years. His research has included numerous advances regarding therapies, often involving interferon. As of 2013, he and his team have uncovered another groundbreaking discovery – published in The New England Journal of Medicine, April 13, 2013 – showing that the new sofosbuvir therapy offers an alternative to standard therapy with interferon for the treatment of two subtypes of hepatitis C. "We have dreamed for years of being able to eliminate interferon from our hepatitis C regimens and this study is one of several that are finally bringing us very close to realizing that goal," says Dr. Jacobson.